Form 4: Alaunos Therapeutics VP of Finance Acquires Stock Options
SEC Form 4 Filing
Ferdinand Groenewald, VP of Finance at Alaunos Therapeutics, acquired stock options on August 14, 2024.
Summary
- Ferdinand Groenewald, VP of Finance at Alaunos Therapeutics, acquired 1,500 employee stock options on August 14, 2024.
- The exercise price of the options is $2.42.
- The options vest in equal quarterly installments over four years, starting November 14, 2024, contingent upon continued service.
- The options expire on August 13, 2034.
Sentiment
Score: 6
Explanation: Neutral sentiment. This is a routine filing related to stock option grants, which is a common practice.
Positives
- The acquisition of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, which is common for corporate insiders who have transactions involving the company's securities. It provides transparency into insider activity.
Stakeholder Impact
- Shareholders may view this as a positive sign if they believe the executive's interests are aligned with theirs.
Key Dates
| Date | Description |
|---|---|
| 08/14/2024 | Date of the stock option transaction. |
| 11/14/2024 | First vesting date of the stock options. |
| 08/13/2034 | Expiration date of the stock options. |
| 08/16/2024 | Date of the Form 4 filing. |
Keywords
Alaunos Therapeutics, stock options, Form 4, insider trading, Ferdinand Groenewald, TCRT, VP Finance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.